公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2018 | Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting | Reck M.; Garassino M.C.; Imbimbo M.; Shepherd F.A.; Socinski M.A.; JIN-YUAN SHIH ; Tsao A.; Lee P.; Winfree K.B.; Sashegyi A.; Cheng R.; Varea R.; Levy B.; Garon E. | Lung Cancer | 28 | 25 | |
2014 | Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer | Pallaud C.; Reck M.; Juhasz E.; Szima B.; CHONG-JEN YU ; Burdaeva O.; Orlov S.; Hilton M.; Archer V.; Mok T. | Lung Cancer | 18 | 16 | |
2014 | A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: Results of the phase II randomized ABIGAIL study (BO21015) | Mok T.; Gorbunova V.; Juhasz E.; Szima B.; Burdaeva O.; Orlov S.; CHONG-JEN YU ; Archer V.; Hilton M.; Delmar P.; Pallaud C.; Reck M. | Journal of Thoracic Oncology | 46 | 44 | |
2010 | A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer | Tan E.-H.; Ramlau R.; Pluzanska A.; Kuo H.-P.; Reck M.; Milanowski J.; Au J.S.-K.; Felip E.; PAN-CHYR YANG ; Damyanov D.; Orlov S.; Akimov M.; Delmar P.; Essioux L.; Hillenbach C.; Klughammer B.; McLoughlin P.; Baselga J. | Annals of Oncology | 35 | 32 | |
2020 | Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ) | Bang Y.-J.; Golan T.; Dahan L.; Fu S.; Moreno V.; Park K.; Geva R.; De Braud F.; Wainberg Z.A.; Reck M.; Goff L.; Laing N.; Mi G.; Oliveira J.M.; Wasserstrom H.; CHIA-CHI LIN | European Journal of Cancer | 85 | 80 | |
2020 | Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY | Nishio M.; Seto T.; Reck M.; Garon E.B.; Chiu C.-H.; Yoh K.; Imamura F.; Park K.; JIN-YUAN SHIH ; Visseren-Grul C.; Frimodt-Moller B.; Zimmermann A.; Homma G.; Enatsu S.; Nakagawa K.; RELAY Study Investigators | Cancer science | 17 | 12 | |
2019 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH ; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Schütte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Atagi S.; Azuma K.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Koyama R.; Hirashima T.; Kaneda H.; Tomii K.; Fujita Y.; Seike M.; Nishimura N.; Kato T.; Ichiki M.; Saka H.; Hirano K.; Nakahara Y.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Juan-Vidal Ó.; Nadal-Alforja E.; Gil-Bazo I.; Ponce-Aix S.; Rubio-Viqueira B.; Alonso Garcia M.; Felip Font E.; Fuentes Pradera J.; Coves Sarto J.; Lin M.-C.; Su W.-C.; Hsia T.-C.; Chang G.-C.; Wei Y.-F.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. | The Lancet Oncology | 397 | 341 | |
2021 | RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non⇓small cell lung cancer | Nakagawa K.; Nadal E.; Garon E.B.; Nishio M.; Seto T.; Yamamoto N.; Park K.; JIN-YUAN SHIH ; Paz-Ares L.; Frimodt-Moller B.; Zimmermann A.H.; Wijayawardana S.; Visseren-Grul C.; Reck M. | Clinical Cancer Research | 28 | 18 | |
2022 | RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability | Nadal E.; Horinouchi H.; JIN-YUAN SHIH ; Nakagawa K.; Reck M.; Garon E.B.; Wei Y.-F.; Kollmeier J.; Frimodt-Moller B.; Barrett E.; Lipkovich O.; Visseren-Grul C.; Novello S. | Drug Safety | 6 | 5 | |